One of thelargest American IDTFs has started using DeepRhythmPlatform (DRP) tocommercially analyze ECG testsCurrentReport No: 18 / 2025

Date: July22, 2025

Legal Basis:Article 17(1) of the MAR Regulation - Confidential Information

With referenceto current report No. 2/2025 of 24 January 2025, in whichMedicalgorithmics S.A. with its registered office in Warsaw (the"Company"; the "Issuer") informed about the conclusion of a significantagreement (the "Agreement") with a U.S.-based diagnostic center (IDTF,the "Partner"), the Management Board of Medicalgorithmics S.A. informsabout the acceptance of the ECG analysis software by the Partnerprovided for in the Agreement.

As the Companyinformed in the previous current report (No. 2/2025), the Agreementcovers the provision of specific services and the licensing ofMedicalgorithmics' leading software, DeepRhythmPlatform (DRP), equippedwith DeepRhythmAI (DRAI) artificial intelligence algorithms for ECGsignal analysis from the Partner's devices.

During theinitial phase, in accordance with the Agreement, the conclusion of whichwas announced by the Company in current report No. 2/2025, the Companycarried out the integration of Company's technology with the Partner'ssoftware and devices. Medicalgorithmics S.A. has made ECG softwareavailable to the Partner for use in the production environment. TheManagement Board of the Company informs that on July 22, 2025, theCompany received a notification of the acceptance of the ECG analysissoftware. In connection with the acceptance, the Partner began to useCompany's technology for ECG study analyses, in accordance with theAgreement.

As the Companyinformed in current report No. 2/2025, the conclusion of this Agreementis a key step in implementing the Company's strategy, as outlined inCurrent Report No. 16/2023 dated June 19, 2023. The strategy aims tosignificantly increase the Company's revenue and profitability(leveraging its high operational leverage) and generate positive cashflows.